TNFSF8 Protéine

N° du produit ABIN7317038

Cette protéine Recombinant TNFSF8 est produite dans HEK-293 Cells.

Aperçu rapide pour TNFSF8 Protéine (ABIN7317038)

Antigène: TNFSF8 (Tumor Necrosis Factor (Ligand) Superfamily, Member 8 (TNFSF8))

Type de proteíne: Recombinant

Origine: Humain

Source: HEK-293 Cells

Pureté: > 90 % as determined by reducing SDS-PAGE.

Détail du produit

Fonction: Recombinant Human CD153/CD30L/TNFSF8 Protein

Séquence: Gln 63-Asp 234

Attributs du produit: A DNA sequence encoding the human CD30L (NP_001235.1) (Gln63-Asp234) was expressed with two additional amino acids (Gly & Pro ) at the N-terminus.

niveau d'endotoxine: < 1.0 EU per μg as determined by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Détail du antigène

Antigène: TNFSF8 (Tumor Necrosis Factor (Ligand) Superfamily, Member 8 (TNFSF8))

Autre désignation: CD153/CD30L/TNFSF8

Sujet:

Background: CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.

Synonym: CD153,CD30L,CD30LG

Poids moléculaire: 19.6 kDa

NCBI Accession: NP_001235